IFNA1 and lymphopenia: This is supported by studies which demonstrate that administration of high dose IFNα or pharmacologic induction of a robust Type I IFN response enhances antiviral immunity [70], [71], while continuous low-dose IFNα treatment drives strong lymphopenia in chronically SIV-infected monkeys [70].